eShowcase: ISI Solutions Platform
Regulatory solution suite from ISI migrates to new platform for improved integration
Regulatory solution suite from ISI migrates to new platform for improved integration
Image Solutions Inc. (Whippany, NJ) has migrated its regulatory product suite for the life sciences industry into the ISI Solutions Platform built on Microsoft's .NET Framework. By moving to the .NET Framework, companies will have one integrated platform from which to manage, review, and publish electronic submissions to the FDA.
The ISI Solutions Platform provides the technology foundation for the company's full suite of products. Its regulatory suite includes its flagship submission products, eCTDXPress and ISIPublisher. These products address the file preparation time in the submissions process. Additional productivity tools and templates are also included in the ISI Solutions Platform.
The .NET Framework gives the suite interoperability with other systems within and outside the company, including document management systems. It also features flexibility, solutions that can be easily scaled to the size of the organization, and common interfaces.
ISI, (973) 560-0404, www.imagesolutions.com
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
